Abbott Laboratories

NYSE:ABT Stock Report

Market Cap: US$190.1b

Abbott Laboratories Future Growth

Future criteria checks 2/6

Abbott Laboratories is forecast to grow earnings and revenue by 12.6% and 6.8% per annum respectively. EPS is expected to grow by 12.7% per annum. Return on equity is forecast to be 20.5% in 3 years.

Key information

12.6%

Earnings growth rate

12.74%

EPS growth rate

Medical Equipment earnings growth16.5%
Revenue growth rate6.8%
Future return on equity20.52%
Analyst coverage

Good

Last updated30 Jan 2026

Recent future growth updates

Recent updates

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

Feb 02

Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)

Jan 03
Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)

Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem

Nov 05
Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem

There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings

Sep 15
There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings

Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices

Apr 16

Abbott Laboratories Basking In A Sharp Turn In Sentiment

Mar 16

Investors Shouldn't Be Too Comfortable With Abbott Laboratories' (NYSE:ABT) Earnings

Feb 28
Investors Shouldn't Be Too Comfortable With Abbott Laboratories' (NYSE:ABT) Earnings

Abbott Laboratories' (NYSE:ABT) Business Is Yet to Catch Up With Its Share Price

Feb 17
Abbott Laboratories' (NYSE:ABT) Business Is Yet to Catch Up With Its Share Price

Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?

Feb 05
Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?

Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)

Jan 23

Abbott Laboratories Q4 2024 Earnings Preview

Jan 08

Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline

Dec 21

Abbott Laboratories: Investors Should Wait For A Pullback

Nov 25

Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Oct 21

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Oct 14

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Sep 11

Earnings and Revenue Growth Forecasts

NYSE:ABT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202855,1359,9739,968N/A16
12/31/202751,5158,8498,836N/A25
12/31/202647,9227,9198,928N/A27
12/31/202544,3286,524N/AN/AN/A
9/30/202543,84313,9266,9179,119N/A
6/30/202543,10913,9286,7759,037N/A
3/31/202542,34413,4516,6578,950N/A
12/31/202441,95013,3516,3518,558N/A
9/30/202441,2175,7616,4868,728N/A
6/30/202440,7255,5465,6547,900N/A
3/31/202440,3265,6084,9237,143N/A
12/31/202340,1095,7015,0597,261N/A
9/30/202339,9595,1424,4926,549N/A
6/30/202340,2265,1405,4887,452N/A
3/31/202341,5055,7856,8238,659N/A
12/31/202243,6536,9057,8049,581N/A
9/30/202245,0307,8578,54110,322N/A
6/30/202245,5488,5208,46810,243N/A
3/31/202244,5147,6958,1529,961N/A
12/31/202143,0757,0428,64810,533N/A
9/30/202142,3087,2089,31411,264N/A
6/30/202140,2336,3438,64410,629N/A
3/31/202137,3385,6937,6099,823N/A
12/31/202034,6084,4495,7247,901N/A
9/30/202032,2213,3464,5876,519N/A
6/30/202031,4443,0734,5646,401N/A
3/31/202032,0953,5394,4766,139N/A
12/31/201931,9043,6664,4986,136N/A
9/30/201931,3553,272N/A5,485N/A
6/30/201930,9352,867N/A5,720N/A
3/31/201930,7232,582N/A5,904N/A
12/31/201830,5782,319N/A6,300N/A
9/30/201830,402802N/A6,175N/A
6/30/201829,575812N/A5,997N/A
3/31/201828,445365N/A6,104N/A
12/31/201727,390344N/A5,570N/A
9/30/201725,1341,971N/A5,100N/A
6/30/201723,6071,055N/A4,312N/A
3/31/201722,3031,384N/A3,870N/A
12/31/201620,8531,056N/A3,203N/A
9/30/201620,708989N/A2,861N/A
6/30/201620,5561,939N/A2,839N/A
3/31/201620,3932,124N/A2,871N/A
12/31/201520,4052,586N/A2,966N/A
9/30/201520,5732,523N/A3,376N/A
6/30/201520,5022,365N/A3,382N/A
3/31/201520,3892,004N/A3,341N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABT's forecast earnings growth (12.6% per year) is above the savings rate (3.3%).

Earnings vs Market: ABT's earnings (12.6% per year) are forecast to grow slower than the US market (15.7% per year).

High Growth Earnings: ABT's earnings are forecast to grow, but not significantly.

Revenue vs Market: ABT's revenue (6.8% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: ABT's revenue (6.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABT's Return on Equity is forecast to be high in 3 years time (20.5%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/02 19:23
End of Day Share Price 2026/01/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abbott Laboratories is covered by 52 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Matthew MiksicBarclays
Adam FeinsteinBarclays